Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
Quarterly results
IDEAYA Biosciences, Inc. (IDYA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "IDEAYA Biosciences, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update • Strong balance sheet of $510.1 million of cash, cash equivalents and marketable securities as of June 30, 2023 anticipated to fund operations into 2027 • Initiated Phase 2/3 registrational trial for darovasertib and crizotinib combination in first-line HLA-A2 negative metastatic UM, and also initiated a separate Phase 2 clinical trial to evaluate single-agent darovasertib as neoadjuvant and adjuvant therapy for primary UM • Targeting darovasertib clinical program updates in Q4 2023, including ctDNA data from Phase 2 MUM trial at ESMO 2023, as well as prevalence of HLA-A2 / serotypes and clinical data update for darovasertib as neoadjuvant therapy in primary UM •..."
05/09/2023 8-K Quarterly results
Docs: "IDEAYA Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update • Strong balance sheet of $351.2 million of cash, cash equivalents and marketable securities as of March 31, 2023 supplemented by $188.7 million estimated net proceeds from closing of underwritten public offering on April 27, 2023, anticipated to fund operations into 2027 • Initiating Phase 2/3 registrational trial in Q2 2023 of darovasertib and crizotinib combination in First-Line HLA-A2 negative MUM, with median PFS as primary endpoint for potential accelerated approval • Reported compelling darovasertib program Phase 2 clinical efficacy, including in First-Line and Any-Line MUM, and additional clinical efficacy as neoadjuvant therapy in primary UM • Targeting da..."
03/07/2023 8-K Quarterly results
Docs: "IDEAYA Biosciences, Inc. Reports 2022 Financial Results and Provides Business Update • Strong balance sheet of ~$373.1 million cash, cash equivalents and marketable securities as of December 31, 2022 is anticipated to fund planned operations into 2026 • Planning regulatory update on potential registration-enabling clinical trial for darovasertib / crizotinib combination in MUM following scheduled FDA meeting in Q1 2023 • Targeting mid-year 2023 darovasertib / crizotinib clinical efficacy update with approximately 20 first-line MUM patients, including confirmed ORR and median PFS; program goals are >20% confirmed ORR and >5 months median PFS • Targeting interim clinical efficacy update from ongoing investigator sponsored trial for darovasertib as neoadjuvant ther..."
11/08/2022 8-K Quarterly results
Docs: "IDEAYA Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update • Strong balance sheet of $393.9 million cash, cash equivalents and marketable securities as of September 30, 2022 is anticipated to fund planned operations into 2026 • Reported Phase 2 interim clinical data for darovasertib and crizotinib combination in MUM; subject to FDA guidance, targeting initiation of potential registrational trial for Daro + Crizo in MUM in Q1 2023 • Reported preliminary clinical proof-of-concept supporting potential darovasertib use in adjuvant uveal melanoma; targeting initiation of company-sponsored trial for Daro in neoadjuvant UM in Q4 2022 • Initiated IDE397 Phase 2 monotherapy expansion cohorts and Phase 1 combination dose escalation ..."
08/15/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
03/15/2022 8-K Quarterly results
Docs: "IDEAYA Biosciences, Inc. Reports 2021 Financial Results and Provides Business Update"
11/15/2021 8-K Quarterly results
Docs: "IDEAYA Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update"
08/10/2021 8-K Quarterly results
Docs: "IDEAYA Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update"
05/10/2021 8-K Quarterly results
03/23/2021 8-K Quarterly results
11/12/2020 8-K Quarterly results
Docs: "IDEAYA Biosciences, Inc. Condensed Statements of Operations and Comprehensive Loss Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019"
08/12/2020 8-K Quarterly results
05/12/2020 8-K Quarterly results
Docs: "IDEAYA Biosciences, Inc. Condensed Balance Sheet Data March 31, December 31, 2020 2019"
03/24/2020 8-K Quarterly results
11/13/2019 8-K Quarterly results
08/12/2019 8-K Investor presentation, Quarterly results
Docs: "IDEAYA Biosciences, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update South San Francisco, CA, August 12, 2019 - IDEAYA Biosciences, Inc. , an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics, provided a business update and announced financial results for the second quarter ended June 30, 2019. “The initiation of our Phase 1/2 basket trial evaluating IDE196 in patients with solid tumors harboring GNAQ/11 mutations is an important step in the clinical development of IDE196. We are identifying and enrolling patients with solid tumors having likely pathogenic GNAQ/11 hotspot mutations that activate the PKC signaling pathway. We believe this ...",
"Investor Presentation of IDEAYA Biosciences, Inc"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy